Needham initiated coverage on Monday for GH Research PLC (NASDAQ:GHRS), citing the company’s lead drug candidate, GH-001, which had demonstrated impressive efficacy in Phase 2 versus competition. • GHRS is showing upward movement. See the full breakdown here.Recently, the company submitted a complete response to the previously announced clinical hold on the Investigational New Drug Application (IND) for GH001 with the U.S. Food and Drug Administration.GH Research received a response from the FDA with only o ...